| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082222 | Drug Discovery Today: Disease Models | 2010 | 9 Pages |
Abstract
Pulmonary hypertension (PHTN) is a major clinical problem, which develops in response to vascular injury or rarely arises spontaneously. The field of neuropeptide biology has been a rich source of biomarkers (like brain natriuretic peptide; BNP) and treatment strategies (like endothelin receptor antagonists; ETRAs) for PHTN. We describe two knockout mouse models from this area, one involving the metallopeptidase, neprilysin (NEP) and the other the neuropeptide, vasoactive intestinal peptide (VIP), that are providing new mechanistic insights into smoke- and hypoxia-induced (secondary) and idiopathic (primary) PHTN, respectively.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Edward C. Dempsey, Zoe L. Loomis, Marilee J. Wick,